As of Apr 2, 2025, the KRYS stock has a PE ratio of 58.01. The calculation is based on the latest EPS of $3.12 and the stock price of $181 per share. A decrease of 19% has been observed in the PE ratio compared to its average of 71.9 of the last four quarters.
The mean historical PE ratio of Krystal Biotech over the last eight years is 99.69. The current 58.01 P/E ratio is 42% lower than the historical average. Looking back at the last eight years, KRYS's PE ratio peaked in the Dec 2023 quarter at 310.15, with a price of $124.06 and an EPS of $0.4. The Sep 2017 quarter marked the lowest point at 0.27, with a price of $9.97 and an EPS of $37.27.
Maximum annual decrease: -83.81% in 2024
Year | PE ratio | PE change | Price | EPS |
---|---|---|---|---|
2024 | 50.21 | -83.81% | $156.66 | $3.12 |
2023 | 310.15 | N/A | $124.06 | $0.4 |
2022 | N/A | N/A | $79.22 | -$5.49 |
2021 | N/A | N/A | $69.95 | -$3.13 |
2020 | N/A | N/A | $60 | -$1.71 |
2019 | N/A | N/A | $55.38 | -$1.2 |
2018 | N/A | N/A | $20.78 | -$0.97 |
2017 | N/A | N/A | $10.52 | -$1.48 |
2016 | N/A | N/A | N/A | -$1.31 |
Year | PE ratio | PE change | Price | EPS |
---|---|---|---|---|
Dec 2024 | 50.21 | -49.25% | $156.66 | $3.12 |
Sep 2024 | 98.93 | 103.1% | $182.03 | $1.84 |
Jun 2024 | 48.71 | -45.79% | $183.64 | $3.77 |
Mar 2024 | 89.86 | -71.03% | $177.93 | $1.98 |
Dec 2023 | 310.15 | N/A | $124.06 | $0.4 |
Sep 2023 | N/A | N/A | $116 | -$1.38 |
Jun 2023 | N/A | N/A | $117.4 | -$5.43 |
Mar 2023 | N/A | N/A | $80.06 | -$5.28 |
Dec 2022 | N/A | N/A | $79.22 | -$5.49 |
Sep 2022 | N/A | N/A | $69.7 | -$5.21 |
Jun 2022 | N/A | N/A | $65.66 | -$4.74 |
Mar 2022 | N/A | N/A | $66.54 | -$4.38 |
Dec 2021 | N/A | N/A | $69.95 | -$3.13 |
Sep 2021 | N/A | N/A | $52.21 | -$2.71 |
Jun 2021 | N/A | N/A | $68 | -$2.5 |
The current PE ratio of KRYS is lower than its 3 and 5-year averages.
Stock name | PE ratio | Market cap |
---|---|---|
KRYS Krystal Biotech Inc | 55.73 | $5.01B |
OLMA Olema Pharmaceuticals Inc | N/A | $230.28M |
OMER Omeros Corp | N/A | $432M |
ONVO Organovo Holdings Inc | N/A | $3.16M |
ORIC Oric Pharmaceuticals Inc | N/A | $370.76M |
ORMP Oramed Pharmaceuticals Inc | N/A | $89.46M |
KRYS stock has a price to earnings ratio of 58.01 as of Apr 2, 2025.
As an average over the last 3 years, KRYS stock has a PE ratio of 119.57.
As an average over the last 5 years, KRYS stock has a PE ratio of 119.57.
Over the last eight years, the Dec 2023 quarter recorded the highest quarterly PE ratio at 310.15.
KRYS's current price to earnings ratio is 42% below its 8-year historical average.
The P/E ratio is obtained by dividing the latest price of a stock by its trailing twelve months EPS. As of today (Apr 2, 2025), Krystal Biotech's share price is $181. The company's earnings per share for the trailing twelve months (TTM) ending Dec 2024 is $3.12. Therefore, Krystal Biotech's PE ratio for today is 58.01. PE RATIO(58.01) = STOCK PRICE($181) / TTM EPS($3.12)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified. Data from and Sharadar.